Antibody therapy for non-Hodgkin's lymphoma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Significant advances in the therapy of non-Hodgkin's lymphoma have been made with the introduction of monoclonal antibodies. The anti-CD20 antibody rituximab has become standard as monotherapy in patients with indolent lymphoma, and in combination with chemotherapy in patients with aggressive lymphoma. A number of new monoclonal antibodies targeting different molecules on lymphoma cells are now in clinical development and show promise both as single agents and in combination therapy. Furthermore, anti-CD20 monoclonal antibodies have been radioconjugated to increase their efficacy. Future studies will therefore be needed to explore the efficacy of combinations of these agents and to develop a rational strategy for their use.

Original languageEnglish (US)
Pages (from-to)175-181
Number of pages7
JournalCurrent Opinion in Molecular Therapeutics
Volume6
Issue number2
StatePublished - Apr 2004

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma
Monoclonal Antibodies
Antibodies
Combination Drug Therapy
Anti-Idiotypic Antibodies
Therapeutics
Rituximab

Keywords

  • Antibody-dependent cellular cytotoxicity
  • Apoptosis
  • Complement
  • Monoclonal antibody
  • Non-Hodgkin's lymphoma
  • Radioimmunoconjugate therapy

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Drug Discovery
  • Pharmacology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Antibody therapy for non-Hodgkin's lymphoma. / Ansell, Stephen Maxted.

In: Current Opinion in Molecular Therapeutics, Vol. 6, No. 2, 04.2004, p. 175-181.

Research output: Contribution to journalArticle

@article{63e9a7ca31f3489ea97da73b10c9ac27,
title = "Antibody therapy for non-Hodgkin's lymphoma",
abstract = "Significant advances in the therapy of non-Hodgkin's lymphoma have been made with the introduction of monoclonal antibodies. The anti-CD20 antibody rituximab has become standard as monotherapy in patients with indolent lymphoma, and in combination with chemotherapy in patients with aggressive lymphoma. A number of new monoclonal antibodies targeting different molecules on lymphoma cells are now in clinical development and show promise both as single agents and in combination therapy. Furthermore, anti-CD20 monoclonal antibodies have been radioconjugated to increase their efficacy. Future studies will therefore be needed to explore the efficacy of combinations of these agents and to develop a rational strategy for their use.",
keywords = "Antibody-dependent cellular cytotoxicity, Apoptosis, Complement, Monoclonal antibody, Non-Hodgkin's lymphoma, Radioimmunoconjugate therapy",
author = "Ansell, {Stephen Maxted}",
year = "2004",
month = "4",
language = "English (US)",
volume = "6",
pages = "175--181",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "2",

}

TY - JOUR

T1 - Antibody therapy for non-Hodgkin's lymphoma

AU - Ansell, Stephen Maxted

PY - 2004/4

Y1 - 2004/4

N2 - Significant advances in the therapy of non-Hodgkin's lymphoma have been made with the introduction of monoclonal antibodies. The anti-CD20 antibody rituximab has become standard as monotherapy in patients with indolent lymphoma, and in combination with chemotherapy in patients with aggressive lymphoma. A number of new monoclonal antibodies targeting different molecules on lymphoma cells are now in clinical development and show promise both as single agents and in combination therapy. Furthermore, anti-CD20 monoclonal antibodies have been radioconjugated to increase their efficacy. Future studies will therefore be needed to explore the efficacy of combinations of these agents and to develop a rational strategy for their use.

AB - Significant advances in the therapy of non-Hodgkin's lymphoma have been made with the introduction of monoclonal antibodies. The anti-CD20 antibody rituximab has become standard as monotherapy in patients with indolent lymphoma, and in combination with chemotherapy in patients with aggressive lymphoma. A number of new monoclonal antibodies targeting different molecules on lymphoma cells are now in clinical development and show promise both as single agents and in combination therapy. Furthermore, anti-CD20 monoclonal antibodies have been radioconjugated to increase their efficacy. Future studies will therefore be needed to explore the efficacy of combinations of these agents and to develop a rational strategy for their use.

KW - Antibody-dependent cellular cytotoxicity

KW - Apoptosis

KW - Complement

KW - Monoclonal antibody

KW - Non-Hodgkin's lymphoma

KW - Radioimmunoconjugate therapy

UR - http://www.scopus.com/inward/record.url?scp=7944220329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7944220329&partnerID=8YFLogxK

M3 - Article

C2 - 15195930

AN - SCOPUS:7944220329

VL - 6

SP - 175

EP - 181

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 2

ER -